Inventor · disambiguated record
Daniel Erlanson
Also filed as: ERLANSON DANIEL · ERLANSON DANIEL A
18 granted patents·20 pending applications·173 citations·filing 2000–2024
94Inventor score
Files withSUNESIS PHARMACEUTICALS INC11CARMOT THERAPEUTICS INC5VIRACTA THERAPEUTICS INC4AMGEN INC2BRAISTED ANDREW C2
Top patents by PatentIndex Score
38 records- 0195US11053226B2KRAS G12C inhibitors and methods of using the sameAMGEN INC·Filed 2019·Granted Jul 6, 2021·25 cites·48 claims
- 0292US9790229B2Bruton's tyrosine kinase inhibitorsBIOGEN MA INC·Filed 2016·Granted Oct 17, 2017·11 cites·21 claims
- 0391US8785440B2Bruton's tyrosine kinase inhibitorsBUI MINNA·Filed 2010·Granted Jul 22, 2014·20 cites·20 claims
- 0489US9249146B2Bruton'S tyrosine kinase inhibitorsBIOGEN IDEC INC·Filed 2014·Granted Feb 2, 2016·9 cites·25 claims
- 0589US8778977B2Pyridinonyl PDK1 inhibitorsLIND KENNETH EGNARD·Filed 2007·Granted Jul 15, 2014·21 cites·15 claims
- 0689US6878743B2Small molecule inhibitors of caspasesSUNESIS PHARMACEUTICALS INC·Filed 2002·Granted Apr 12, 2005·38 cites·43 claims
- 0784US9029359B2Heteroaryl Btk inhibitorsBUI MINNA·Filed 2010·Granted May 12, 2015·12 cites·18 claims
- 0884US2024246988A1Bruton's tyrosine kinase inhibitorsVIRACTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0984US2024294524A1Heterocyclic compounds useful as pdk1 inhibitorsVIRACTA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1082US10577374B2Bruton's tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2017·Granted Mar 3, 2020·2 cites·18 claims
- 1181US6143776ATosylproline analogs as thymidylate synthase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2000·Granted Nov 7, 2000·12 cites·20 claims
- 1280US10030016B2Heterocyclic compounds useful as PDK1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2015·Granted Jul 24, 2018·2 cites·16 claims
- 1378US2023046457A1Bruton's tyrosine kinase inhibitorsVIRACTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1477US6919178B2Extended tethering approach for rapid identification of ligandsSUNESIS PHARMACEUTICALS INC·Filed 2001·Granted Jul 19, 2005·14 cites·27 claims
- 1577US2023113598A1Heterocyclic compounds useful as pdk1 inhibitorsVIRACTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1670US9546165B2Heterocyclic compounds useful as PDK1 inhibitorsARNDT JOSEPH·Filed 2010·Granted Jan 17, 2017·2 cites·12 claims
- 1770US2021070752A1Heterocyclic compounds useful as pdk1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1870US2020399283A1Bruton's tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1966US12281149B2Modulators of G-protein coupled receptorsCARMOT THERAPEUTICS INC·Filed 2022·Granted Apr 22, 2025·0 cites·11 claims
- 2066US2024383960A1Modulators of G-Protein Coupled ReceptorsCARMOT THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2165US7214487B2Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidatesSUNESIS PHARMACEUTICALS INC·Filed 2003·Granted May 8, 2007·5 cites·19 claims
- 2263US2019119268A1Heterocyclic compounds useful as pdk1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2362US9873693B2Methods of treatment using pyridinonyl PDK1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2014·Granted Jan 23, 2018·0 cites·15 claims
- 2460US10107798B2Methods of chemotype evolutionHANSEN STIG·Filed 2009·Granted Oct 23, 2018·0 cites·57 claims
- 2560US2018370966A1Methods of treatment using pyridinonyl pdk1 inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2659US2025340548A1Kras g12c inhibitorsFRONTIER MEDICINES CORP·Filed 2022·Application pending·0 cites
- 2759US2008293777A1Weight Loss TreatmentERLANSON DANIEL A·Filed 2008·Application pending·0 cites
- 2859US2023357347A1Modulators of g-protein coupled receptorsCARMOT THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2957US2024425513A1Oxazole, oxadiazole, and indole derivatives for the inhibition of usp28CARMOT THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3056US2005287596A9Novel ligands and libraries of ligandsBRAISTED ANDREW C·Filed 2002·Application pending·0 cites
- 3153US2025093362A1High-throughput engineering of molecular gluesFRONTIER MEDICINES CORP·Filed 2022·Application pending·0 cites
- 3252US2012077711A1Novel Ligands and Libraries of LigandsBRAISTED ANDREW C·Filed 2011·Application pending·0 cites
- 3352US2005186630A1Extended tethering approach for rapid identification of ligandsFiled 2005·Application pending·0 cites
- 3452US2018238863A1Chemical synthesisHANSEN STIG·Filed 2018·Application pending·0 cites
- 3550US11572374B2N-cyano-7-azanorbornane derivatives and uses thereofAMGEN INC·Filed 2019·Granted Feb 7, 2023·0 cites·6 claims
- 3646US11535660B1Modulators of G-protein coupled receptorsCARMOT THERAPEUTICS INC·Filed 2019·Granted Dec 27, 2022·0 cites·34 claims
- 3735US2004014140A1Methods for identifying allosteric sitesFiled 2003·Application pending·0 cites
- 3835US2011301235A1Organoselenium compounds and uses thereofERLANSON DANIEL A·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Daniel Erlanson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →